PTC Therapeutics announced its second quarter 2025 financial results on August 7, 2025, reporting total revenues of $178.9 million. This represents a 4.2% decrease compared to total revenues in the second quarter of 2024. Net product revenue for the quarter was $118.3 million, down from $133.2 million in Q2 2024, while royalty revenue increased to $57.6 million from $53.2 million.
The company reported a net loss attributable to common stockholders of $64.8 million, or $0.83 per diluted share, which is a reduction from the net loss of $99.2 million reported in Q2 2024. Non-GAAP research and development expenses were $104.0 million, and non-GAAP selling, general, and administrative expenses were $75.7 million.
As of June 30, 2025, PTC Therapeutics maintained a strong financial position with cash, cash equivalents, and marketable securities totaling $1.99 billion. The company narrowed its full-year 2025 total revenue guidance to a range of $650 million to $800 million, reflecting ongoing commercialization efforts and pipeline investments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.